Integra LifeSciences (NASDAQ:IART) Stock Price Down 7.7% on Analyst Downgrade

Integra LifeSciences Holdings Corporation (NASDAQ:IART)’s share price traded down 7.7% during mid-day trading on Monday after Wells Fargo & Company lowered their price target on the stock from $13.00 to $12.00. Wells Fargo & Company currently has an equal weight rating on the stock. Integra LifeSciences traded as low as $10.53 and last traded at $10.50. 281,983 shares were traded during mid-day trading, a decline of 61% from the average session volume of 721,196 shares. The stock had previously closed at $11.38.

Other analysts also recently issued research reports about the stock. Truist Financial reissued a “hold” rating and set a $13.00 price target (down from $15.00) on shares of Integra LifeSciences in a research report on Monday, November 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of Integra LifeSciences in a research note on Monday, December 29th. JPMorgan Chase & Co. lifted their price target on Integra LifeSciences from $12.00 to $13.00 and gave the stock an “underweight” rating in a research note on Friday, October 31st. Wall Street Zen upgraded Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Finally, Citigroup reduced their target price on Integra LifeSciences from $12.00 to $11.00 and set a “sell” rating on the stock in a report on Friday, October 31st. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Reduce” and a consensus target price of $14.80.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Allianz Asset Management GmbH lifted its holdings in Integra LifeSciences by 88.7% during the 3rd quarter. Allianz Asset Management GmbH now owns 433,738 shares of the life sciences company’s stock worth $6,215,000 after buying an additional 203,834 shares during the period. Hussman Strategic Advisors Inc. bought a new position in shares of Integra LifeSciences in the 3rd quarter worth about $2,407,000. Systematic Financial Management LP lifted its stake in shares of Integra LifeSciences by 12.8% in the 2nd quarter. Systematic Financial Management LP now owns 1,056,920 shares of the life sciences company’s stock valued at $12,968,000 after purchasing an additional 120,086 shares during the period. Campbell & CO Investment Adviser LLC acquired a new position in shares of Integra LifeSciences in the 2nd quarter valued at about $632,000. Finally, Edgestream Partners L.P. bought a new stake in shares of Integra LifeSciences during the 2nd quarter valued at about $739,000. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Stock Up 1.2%

The firm has a market cap of $823.05 million, a price-to-earnings ratio of -1.57 and a beta of 1.02. The firm has a 50 day moving average of $11.88 and a 200 day moving average of $13.14. The company has a quick ratio of 1.46, a current ratio of 2.54 and a debt-to-equity ratio of 1.66.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Thursday, February 26th. The life sciences company reported $0.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.04. The firm had revenue of $434.93 million for the quarter, compared to analysts’ expectations of $429.62 million. Integra LifeSciences had a positive return on equity of 14.76% and a negative net margin of 31.58%.The company’s revenue for the quarter was down 1.7% compared to the same quarter last year. During the same period in the prior year, the business earned $0.97 EPS. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. As a group, sell-side analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.